Our Science: Broad neoantigen delivery + CD 28 costimulation repair

EV Therapeutics is developing novel neoantigen-based immunotherapies using our proprietary modified tumor-derived extracellular vesicle (mTEV) technology.  Our mTEV's are capable of restoring the normal anti-tumor immune response in cancer patients allowing checkpoint inhibitor therapies to work. 

Having completed eight years of mechanistic and preclinical studies, our data suggests the possibility of extending the progression-free survival (PFS) and overall survival (OS) outcomes of advanced colorectal cancer patients and other solid tumor gastrointestinal cancers.

mTEV functions by replenishing low number of neoantigens present and help stimulate the immune system by jump starting the immune surveillance functions (e.g. just like jump starting a "dead" car battery with external cables).  Our strong immunogenic stimulation is achieved by blocking the principal inhibiting miRNA that halt the CD28/CD80 co-stimulatory protein expression in the patient's natural immune system (i.e. T-lymphocytes). This in turn repairs and reactivates  a patients’ normal anti-tumor immune response permitting checkpoint inhibitors (e.g. KEYtruda and OPDIVO)to help sustain the immune activation for long term clinical benefit.